Right to Try Clarification Act
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in house (Mar 28, 2023)
Right to Try Clarification Act
This bill specifies that investigational drugs that are provided via the Right to Try pathway are exempt from restrictions that would otherwise apply under the Controlled Substances Act (e.g., restrictions on the use or possession of schedule I controlled substances).
The Right to Try pathway allows drug manufacturers to provide certain investigational drugs for which a Phase I clinical trial has been completed, but that have not yet received approval from the Food and Drug Administration, directly to individuals who have imminently life-threatening diseases or conditions and who have exhausted other treatment options and are unable to participate in clinical trials.
What just happenedApr 7, 2023
Referred to the Subcommittee on Health.
Who’s behind it
- Introduced in HouseMar 28, 2023
- Apr 7, 2023Committee
Referred to the Subcommittee on Health.
Health Subcommittee - Mar 28, 2023IntroReferralH11100
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Judiciary Committee - Mar 28, 2023IntroReferralH11100
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Energy and Commerce Committee - Mar 28, 2023IntroReferralB00100
Sponsor introductory remarks on measure. (CR E267)
- Mar 28, 2023IntroReferralIntro-H
Introduced in House
- Mar 28, 2023IntroReferral1000
Introduced in House